Adam Talley, MD
Urology · Mobile, ALNPI 1366973141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Boston Scientific at 30.2% of the total. That places this record below the midpoint for urology clinicians in AL, where the typical reported total is $3,591.
Across 90 payments — averaging $40.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Baxter Healthcare$307
- Dendreon Pharmaceuticals LLC$272
- Procept Biorobotics Corporation$253
- Johnson & Johnson$249
- Urogen Pharma, Inc.$244
- plus $1K from 22 others
Across 1 payment — averaging $7000.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Cornerstone Urology Network, LLC$7K
What the payments were for
- Food & beverage$3,55998%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 14 | $1,099 |
| Baxter Healthcare | 3 | $307 |
| Dendreon Pharmaceuticals LLC | 5 | $272 |
| Procept Biorobotics Corporation | 3 | $253 |
| Johnson & Johnson | 12 | $249 |
| Urogen Pharma, Inc. | 8 | $244 |
| Teleflex LLC | 2 | $227 |
| Sumitomo Pharma America, Inc. | 8 | $140 |
| Intuitive Surgical | 1 | $133 |
| Pfizer | 6 | $107 |
| Myriad Genetic Laboratories, Inc. | 5 | $100 |
| Astellas Pharma US Inc | 1 | $85 |
| Novartis | 4 | $69 |
| Conmed Corporation | 1 | $68 |
| Endo USA, Inc. | 2 | $42 |
| Antares Pharma, Inc. | 2 | $33 |
| Laborie Medical Technologies Corp. | 1 | $30 |
| AbbVie | 2 | $30 |
| Urovant Sciences Inc | 1 | $22 |
| Merck | 1 | $20 |
| Tolmar, Inc. | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| 180 Medical, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Myovant Sciences Inc. | 1 | $12 |
| Mission Pharmacal Company | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$340
- AQUABEAM SYSTEM$160
- GENERAL ERECTILE DYSFUNCTION$140
- PROVENGE$138
- UroLift System$134
- Da Vinci Surgical System$133
- FLOSEAL$121
- JELMYTO$113
- GENERAL BPH$102
How this compares
$3,644 in reported general payments places this provider in the 50th percentile of 179 urology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 94 | $53,215 |
| MyrbetriqMirabegron | 94 | $45,229 |
| Trospium Chloride | 244 | $12,058 |
| Estradiol | 129 | $8,346 |
| Testosterone Cypionate | 111 | $3,300 |
| Tamsulosin Hcl | 307 | $2,615 |
| Cefdinir | 72 | $1,419 |
| Methenamine Hippurate | 28 | $1,308 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 44 | $900 |
| Testosterone | 11 | $839 |
| Cabergoline | 11 | $684 |
| Celecoxib | 12 | $601 |
| Oxybutynin Chloride ErOxybutynin Chloride | 50 | $524 |
| Terazosin Hcl | 11 | $492 |
| Betamethasone Dipropionate | 14 | $490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $140 | $53,21594 claims |
| Astellas Pharma US IncMyrbetriq | $85 | $45,22994 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 179 urology providers in Alabama.
Other urology in Mobile
- Lorie FleckMobile$26K
- Zachary ReardonMobile$19K
- Ted KleinMobile$18K
- Austin YoungerMobile$18K
- William BlaylockMobile$13K
- Guy OswaltMobile$9K
- Kristie Blanchard-BurchMobile$8K
- Paul ScottMobile$8K
- William SandersonMobile$7K
- Robert HelmMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.